• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Peloton Therapeutics Inc.

Headquarters: Dallas, TX, United States
Website: N/A
Year Founded: 2010
Status: Acquired

BioCentury | Dec 16, 2023
Finance

Dec. 15 Quick Takes: Pfizer, Nona in ADC deal

Plus: FDA approves Padcev/Keytruda for 1L advanced urothelial cancer, obesity play Fractyl files for IPO and updates from Merck, Syndax, AC Immune, BMS 
BioCentury | Sep 20, 2023
Finance

Sept. 19 Quick Takes: RNA editing company Airna emerges with $30M round led by Arch

Plus: Longevity-focused VC debuts and updates from Recode, Merck, Taysha and Paratek 
BioCentury | Aug 19, 2023
Regulation

Aug. 18 Quick Takes: FDA approvals for Regeneron, Neurocrine  

Plus: Priority review for full approval of Calliditas’ Tarpeyo and updates from Astellas-Iveric, Merck, Arch newco TFC 
BioCentury | Feb 1, 2022
Management Tracks

Senti Bio, Sangamo alum Lee joins Lyell as CSO

Plus Leaming and Posner retire from Biogen’s board, Bourdon moves to Leo, and updates from Keros, NeoTX and more
BioCentury | Dec 23, 2021
Product Development

First-in-class drugs fill FDA’s 2021 class of new approvals

Products against new targets accounted for nearly one third of NMEs, and fewer of them were for cancer than you might think
BioCentury | Aug 24, 2021
Emerging Company Profile

Atavistik: Identifying allosteric modulators of metabolic proteins

Emerging Company Profile: Utah spinout launching with $60M to identify
BioCentury | Aug 13, 2021
Regulation

FDA nod in rare disease is first fruit from Merck’s Peloton takeout

FDA’s approval of Merck’s Welireg belzutifan to treat von Hippel-Landau disease represents the first marketing authorization of a therapy the pharma obtained via its $1 billion-plus
BioCentury | Jun 26, 2021
Finance

After series of exits, Vida details plans to deploy $825M third fund, its largest yet

Nine IPOs, four M&A events in young firm’s rearview mirror
BioCentury | May 26, 2021
Finance

Building on discovery platform and early deals, CBC-backed NiKang adds $200M in crossover series C round

With backing from high-profile crossover investors, four-year-old company taking wholly-owned HIF2A program into clinic
BioCentury | May 14, 2021
Emerging Company Profile

Flare: Using ‘switch sites’ to modulate previously intractable transcription factors

Emerging Company Profile: With $82M series A, Third Rock-backed start-up uses structural insights into factors’ conformations
Items per page:
1 - 10 of 49